TY - JOUR
T1 - Long-term outcome of ablation of anal high-grade squamous intraepithelial lesions
T2 - Recurrence and incidence of cancer
AU - Goldstone, Stephen E.
AU - Johnstone, Andrew A.
AU - Moshier, Erin L.
PY - 2014/3
Y1 - 2014/3
N2 - BACKGROUND: High-grade dysplasia is the anal carcinoma precursor. Clinicians ablate high-grade dysplasia with laser, electrocautery, and infrared coagulation to prevent cancer. OBJECTIVE: The aim of this study was to determine the long-term effectiveness of high-grade dysplasia ablation and the incidence of cancer. DESIGN: This study is a retrospective chart review of patients who were treated for high-grade dysplasia from February 1998 until May 2012. SETTING: This study was conducted in a surgical practice screening patients for anal cancer and high-grade dysplasia. PATIENTS: The patients identified were HIV-positive and -negative men who have sex with men. INTERVENTION: The ablation of high-grade dysplasia was performed. MAIN OUTCOME MEASURES: The primary outcomes measured were the probability of high-grade dysplasia recurrence postablation and the incidence of cancer. RESULTS: Four hundred fifty-six HIV-positive men who have sex with men (mean age, 45 ± 9 years) and 271 HIV-negative men who have sex with men (mean age, 41 ± 11 years) followed for a median of 2.2 (range, 0.213) years underwent high-grade dysplasia ablation by laser, infrared coagulation, and/or electrocautery. Median time to recurrence was 6.8 and 6.9 months for HIV-positive and -negative patients. Kaplan-Meier curves predict a rate of recurrence 1 year after the first ablation for HIV-positive and -negative patients of 53% (95% CI, 49%58%) and 49% (95% CI, 43%55%). At 2 and 3 years, the rate of recurrence was 68% (95% CI, 63%73%) and 77% (95% CI, 7%282%) for HIV-positive patients and 57% (95% CI, 51%64%) and 66% (95% CI, 59%73%) for HIV-negative patients. The median number of recurrent lesions was ≤2 for HIV-positive patients and ≤1 for HIV-negative patients. Recurrence increased with HIV infection (HR, 1.3; 95% CI, 1.11.6) and each additional lesion treated (HR 1.6, 95% CI, 1.11.2). Five HIV-positive men who have sex with men developed cancer. The Kaplan-Meier probability of cancer 3 years postablation was 1.97% (95% CI, 0.73%5.2%). LIMITATIONS: This is a retrospective study by 1 surgeon who has extensive experience treating anal dysplasia. There was no pathology review, and the type of recurrence cannot be definitively determined because the location could be inaccurate. CONCLUSIONS: Patients undergoing ablation of intraanal high-grade dysplasia have high recurrence, but the probability of developing anal cancer is low. HIV infection and increased number of high-grade dysplasias increases the risk of recurrence.
AB - BACKGROUND: High-grade dysplasia is the anal carcinoma precursor. Clinicians ablate high-grade dysplasia with laser, electrocautery, and infrared coagulation to prevent cancer. OBJECTIVE: The aim of this study was to determine the long-term effectiveness of high-grade dysplasia ablation and the incidence of cancer. DESIGN: This study is a retrospective chart review of patients who were treated for high-grade dysplasia from February 1998 until May 2012. SETTING: This study was conducted in a surgical practice screening patients for anal cancer and high-grade dysplasia. PATIENTS: The patients identified were HIV-positive and -negative men who have sex with men. INTERVENTION: The ablation of high-grade dysplasia was performed. MAIN OUTCOME MEASURES: The primary outcomes measured were the probability of high-grade dysplasia recurrence postablation and the incidence of cancer. RESULTS: Four hundred fifty-six HIV-positive men who have sex with men (mean age, 45 ± 9 years) and 271 HIV-negative men who have sex with men (mean age, 41 ± 11 years) followed for a median of 2.2 (range, 0.213) years underwent high-grade dysplasia ablation by laser, infrared coagulation, and/or electrocautery. Median time to recurrence was 6.8 and 6.9 months for HIV-positive and -negative patients. Kaplan-Meier curves predict a rate of recurrence 1 year after the first ablation for HIV-positive and -negative patients of 53% (95% CI, 49%58%) and 49% (95% CI, 43%55%). At 2 and 3 years, the rate of recurrence was 68% (95% CI, 63%73%) and 77% (95% CI, 7%282%) for HIV-positive patients and 57% (95% CI, 51%64%) and 66% (95% CI, 59%73%) for HIV-negative patients. The median number of recurrent lesions was ≤2 for HIV-positive patients and ≤1 for HIV-negative patients. Recurrence increased with HIV infection (HR, 1.3; 95% CI, 1.11.6) and each additional lesion treated (HR 1.6, 95% CI, 1.11.2). Five HIV-positive men who have sex with men developed cancer. The Kaplan-Meier probability of cancer 3 years postablation was 1.97% (95% CI, 0.73%5.2%). LIMITATIONS: This is a retrospective study by 1 surgeon who has extensive experience treating anal dysplasia. There was no pathology review, and the type of recurrence cannot be definitively determined because the location could be inaccurate. CONCLUSIONS: Patients undergoing ablation of intraanal high-grade dysplasia have high recurrence, but the probability of developing anal cancer is low. HIV infection and increased number of high-grade dysplasias increases the risk of recurrence.
KW - Anal cancer
KW - HIV
KW - High-grade dysplasia
KW - Human papillomavirus
UR - http://www.scopus.com/inward/record.url?scp=84897571810&partnerID=8YFLogxK
U2 - 10.1097/DCR.0000000000000058
DO - 10.1097/DCR.0000000000000058
M3 - Article
C2 - 24509453
AN - SCOPUS:84897571810
SN - 0012-3706
VL - 57
SP - 316
EP - 323
JO - Diseases of the Colon and Rectum
JF - Diseases of the Colon and Rectum
IS - 3
ER -